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neonatal hypoglycaemia 53%, foetal loss 11%, preterm deliv-
ery 22%, obstetric complications 33%, congenital malforma-
tions 5%, birth weight >4000 g 20%, and other adverse events
12%. The mean inpatient cost per subject was 4589
(SD  3961). The main costs were admission for pre-term
infants (3089, SD  3508), adverse events and obstetric com-
plications (532, SD  839), and normal delivery costs (968,
SD  328). The mean cost was around four times the average
cost of delivery in a UK hospital (1078). In England and
Wales around 5250 women with type 1 diabetes give birth
every year. The excess cost of these births to the NHS is around
18.4 million per annum. CONCLUSION: Inpatient costs
are high in pregnant women with type 1 diabetes. Successful
intervention in this group could improve health outcomes and
substantially reduce cost.
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OBJECTIVES: Hemoglobin A1c (HbA1c), a clinical measure of
ambient blood glucose concentrations over the previous 3
month time period, is recognized as a surrogate measure for
the risk of complications among patients with diabetes. The
purpose of this research is to quantify the impact of changes
in glycemic control on diabetes-related medical costs.
METHODS: Data from the i3 LabRx Database were used for
this study. Individuals were included in the analysis if they had
two diagnoses of type 2 diabetes (ﬁrst diagnosis identiﬁed as
the index date), had one valid HbA1c test result recorded in the
six months prior to the index date and had at least one valid
HbA1c test result recorded in the twelve months post index
date (N = 2,239). Multivariate regressions were used to
examine the relationship between the change in HbA1c from
the post-period to the pre-period on diabetes related costs,
while controlling for patient characteristics, general health
status, comorbidities, timing between the post and pre-period
HbA1c tests, and initial value of HbA1c. RESULTS: Thirty
percent of the individuals in this sample were found to have an
initial HbA1c value greater than 7. Results from the multivari-
ate analyses indicate that after controlling for other factors
which may impact diabetes-related costs, a one point reduction
in HbA1c value was associated with a $433 reduction in total
one-year diabetes-related medical costs (p = 0.0033). In addi-
tion, a one point reduction in HbA1c value was also associated
with a signiﬁcant reduction in diabetes-related outpatient
costs (-$127, p = 0.0268) as well as a signiﬁcant reduction in
diabetes-related outpatient prescription drug costs (-$293,
p < 0.0001). CONCLUSION: Evidence from this analysis indi-
cates that the direct medical costs of treating type 2 diabetes
are signiﬁcantly reduced as HbA1c values are reduced. These
results highlight that there are savings associated with a one
point reduction in patients’ glycemic control.
PDB46
COST-UTILITY OF INSULIN DETEMIRVERSUS NPH FORTYPE
1 DIABETES PATIENTSTREATED WITH BASAL-BOLUS
THERAPY IN A FRENCH SETTING.A MODELING EVALUATION
BASED ON RESULTS FROM A META-ANALYSIS OFTHREE
CLINICALTRIALS
Scheijbeler H1,Aagren M2, Nielsen S2,Valentine WJ3, Goodall G3,
Kotchie R1
1IMS Health, London, UK, 2Novo Nordisk A/S,Virum, Denmark, 3IMS
Health, Basel, Switzerland
OBJECTIVES: The aim of this study was to estimate the cost-
utility of type 1 diabetes patients treated with detemir based
basal-bolus therapy versus neutral protamine Hagedorn (NPH)
insulin based basal-bolus therapy in France using results
obtained from a meta-analyses of three clinical trials. The meta-
analyses demonstrated a short-term improvement for detemir
over NPH in HbA1c (0.13% points lower), a decrease in
hypoglycemic events (by 4%) and lower body mass index (BMI)
(0.21 kg.m-2). METHODS: A published, validated, peer-
reviewed computer simulation model of diabetes (the CORE
Diabetes Model) was used to project short-term results obtained
from the ﬁxed-effects meta-analysis to long-term clinical and cost
outcomes (including life quality adjusted life expectancy, inci-
dence of complications, and direct medical costs), when basal
detemir or NPH is used in combination with either insulin aspart
or human soluble insulin. Probabilities of complications were
derived from landmark clinical and epidemiological studies.
The costs of treating complications and appropriate baseline
comorbidities were retrieved from published sources and France
speciﬁc mortality rates applied. Total direct medical costs
(complications + treatment costs) were projected over patient
lifetimes, and future costs and clinical beneﬁts discounted at 3%
per annum. RESULTS: Therapeutic beneﬁts of superior glycemic
control, lower hypoglycemic event rates and reduced BMI asso-
ciated with detemir based basal-bolus therapy led an increase in
quality-adjusted life expectancy of 0.190 years (7.38  0.09
versus 7.18  0.09) versus NPH. Increased total lifetime costs/
patient of €2,370 (€75,477  2109 versus €73,106  2165)
with detemir resulted in an incremental cost-effectiveness ratio of
€12,477 per quality-adjusted life year (QALYs) gained. CON-
CLUSION: Therapeutic improvements demonstrated in the
meta-analyses of detemir can be reasonably expected to lead to
decreases in long-term complications, improvements in quality-
adjusted life expectancy and a cost-effectiveness ratio which falls
well below a range considered to represent good value for money
(<€50,000/QALY gained).
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OBJECTIVES: To evaluate long-term economic outcomes in the
Swedish setting for type 2 diabetes patients treated with either
mealtime insulin aspart (IAsp, NovoRapid) or human insulin
(HI) as part of basal-bolus therapy, based on ﬁndings from the
European PREDICTIVE study (Predictable Results and Experi-
ence in Diabetes through Intensiﬁcation and Control to Target:
an International Variability Evaluation). METHODS: The
CORE Diabetes Model, a published and validated computer
simulation model was used to project long-term outcomes and
account lifetime costs for patients receiving either IAsp or HI.
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Treatment effects (improvements in HbA1c, hypoglycemic event
rates and changes in body weight) and cohort characteristics
(mean age 61.6 years, diabetes duration 13.2 years, HbA1c
8.2%, BMI 29.8 kg/m2) were taken from PREDICTIVE and
supplemented with Sweden speciﬁc patient data. Costs were
retrieved from published sources and expressed in 2005
Swedish Kronor (SEK) from both a third party payer and soci-
etal perspective. Total costs were projected over a 50-year time
horizon and discounted at 3% per annum. RESULTS: Over
patient lifetimes IAsp treatment was associated with lower
mean direct medical costs per patient of approximately SEK
8,248 per patient versus HI (SEK 405,910  16,358 versus
SEK 414,158  15,544 respectively). Savings were due to
reduced costs associated with diabetes-related complications
for IAsp compared to HI (difference SEK 14,886) despite
increased treatment and patient management costs (difference
SEK 6,641). Including indirect costs in the analysis increased
the cost savings associated with IAsp treatment to approxi-
mately SEK 10,717 (SEK 521,538  22,106 versus SEK
532,226  21,342). CONCLUSION: Over patient lifetimes,
IAsp treatment was projected to result in overall cost savings
compared to HI when accounting costs from both a health care
payer perspective and from a societal perspective in the Swedish
setting.
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OBJECTIVES: The aim of this study was to investigate the
annual use of medical resources (outpatient visits and current
drug use) and lost productivity (days off work) for people with
T2D with increasing BMI. METHODS: A retrospective analysis
was conducted in United States based on a sample of T2Ds
from the Adelphi Metabolic Syndrome Disease Speciﬁc Pro-
gramme (a large cross sectional study) in 2006 with 643 people
diagnosed with T2D, aged between 35 to 64 years and a
BMI°Ý 20 kg/m2 (based on physician reported height and
weight). People were stratiﬁed according to their BMI; normal/
overweight (20–29.99 kg/m2; n = 110), obese (30–34.99 kg/m2;
n = 178)); very obese (35–39.99 kg/m2; n = 170) and morbidly
obese (>39.99 kg/m2; n = 185). The cohort had an average age
of 53 years, 58% male, and 69% Caucasians. RESULTS: For
people with T2D who was normal/overweight, mean number of
total drugs used for any condition was 4.7. The number of
annual visits to health professionals (PCP, cardiologist, diabetes
specialist, diabetes nurse, other doctor/nurse) was 5.9. The rate
ratio i.e. the mean resource utilization relative to the utilization
in the normal/overweight group for people with T2D who was
obese, very obese and morbidly obese, respectively, were 1.08,
1.15, and 1.32 for total drug use, 1.75, 2.37, and 3.37 for
percentage of people using more than 2 diabetes drugs, and
1.21, 1.31, and 1.39 for annual number of visits to health pro-
fessionals. People not retired had an average annual number of
days off work due to CV or diabetes complications of 1.5 for
the normal/overweight group, with 3.2 for the obese group.
CONCLUSION: These ﬁndings suggest a positive correlation
between BMI and medical resources. The impact of obesity on
resource use is particularly evident in people with T2D in the
high obesity groups.
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OBJECTIVES: In the UK, the role of insulin initiation has tradi-
tionally been one for specialist (secondary care) diabetes teams
(SDT) but this trend is changing with primary care increasingly
taking a leading role. In order to appropriately plan services, all
relevant costs need to be considered. This analysis compares the
estimated costs of insulin initiation using different models of
service delivery—combinations of primary vs secondary care ini-
tiation and group vs individual sessions. METHODS: Using pub-
lished UK literature, the resources used for 4 different service
models were estimated, associated unit costs attached and
total costs estimated over the ﬁrst 3 months of insulin therapy.
RESULTS: In the secondary care led models, average costs were
£221 per person for an individual start over the 3 month period.
As expected, estimated costs for group start sessions were lower
than for individual starts (average £187). In a primary care
initiation model, the average per patient costs were only slightly
lower (£139 individual start, £190 group start). These costs are
higher than the costs of the insulin therapy over the same time
period (average £120) and key cost components were resources
of associated health care professionals (HCP) and length of ses-
sions with the relevant HCP, commonly assumed to be a diabetes
specialist nurse CONCLUSION: Details of the range of resources
used at the point of insulin initiation are not readily available in
the literature. This analysis suggests that signiﬁcant resources are
required compared with the medication costs over this initiation
period. The amount of time spent with the range of appropriate
HCPs is the key driver of cost. Many other factors need consid-
eration when deciding upon appropriate service models including
the experience of the HCPs, the complexity of the insulin regimen
and the degree of self-ownership and satisfaction by the patient.
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OBJECTIVES: In the long term there is a high rate of sulphony-
lurea (SU) prescription on oral antidiabetics (OAD) in Slovakia
compared to DM treatment standards in other countries.
Although this rate is decreasing slowly, there is a need to force the
prescription habits improvement in diabetic patients. Our objec-
tive was to use collected data and analyse prescription habits
of diabetologists with a focus on SU and biguanides rate.
METHODS: We used claims data of reimbursed medicines in
2005 of one Slovak health insurance fund. Diabetic patient was
identiﬁed as the one with at least two prescriptions regarding
DM diagnosis on annual basis. SU rate compared to the total SU
and metformin prescription was calculated for each diabetologist
on the basis of expenditure in DDDs. RESULTS: We identiﬁed
13,481 diabetics (7% of total DM patients undergoing pharma-
cotherapy in Slovakia). These patients were treated by 212
diabetologists. Average SU verus biguanides rate was 59%.
Worldwide, this rate stands for approximately 40%. This differ-
ence requires further steps so the doctors were categorized in
deciles for purposes of targeted audit. Furthermore, we calcu-
lated the savings if patients would go to biguanides instead of SU.
CONCLUSION: Claims data are an effective tool for auditing of
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